{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:04:59Z","timestamp":1791561899284,"version":"4.3.4"},"reference-count":92,"publisher":"Bentham Science Publishers Ltd.","issue":"1","funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2018YFC1603005"],"award-info":[{"award-number":["2018YFC1603005"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDM"],"published-print":{"date-parts":[[2021,3,22]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Human cytochrome P450 enzyme 1A2 (CYP1A2) is one of the most important cytochrome P450\n(CYP) enzymes in the liver, accounting for 13% to 15% of hepatic CYP enzymes. CYP1A2 metabolises many\nclinical drugs, such as phenacetin, caffeine, clozapine, tacrine, propranolol, and mexiletine. CYP1A2 also\nmetabolises certain precarcinogens such as aflatoxins, mycotoxins, nitrosamines, and endogenous substances\nsuch as steroids. The regulation of CYP1A2 is influenced by many factors. The transcription of CYP1A2 involves\nnot only the aromatic hydrocarbon receptor pathway but also many additional transcription factors, and\nCYP1A2 expression may be affected by transcription coactivators and compression factors. Degradation of\nCYP1A2 mRNA and protein, alternative splicing, RNA stability, regulatory microRNAs, and DNA methylation\nare also known to affect the regulation of CYP1A2. Many factors can lead to changes in the activity of\nCYP1A2. Smoking, polycyclic aromatic hydrocarbon ingestion, and certain drugs (e.g., omeprazole) increase\nits activity, while many clinical drugs such as theophylline, fluvoxamine, quinolone antibiotics, verapamil,\ncimetidine, and oral contraceptives can inhibit CYP1A2 activity. Here, we review the drugs metabolised by\nCYP1A2, the metabolic mechanism of CYP1A2, and various factors that influence CYP1A2 metabolism. The\nmetabolic mechanism of CYP1A2 is of great significance in the development of personalised medicine and\nCYP1A2 target-based drugs.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389200221999210101233135","type":"journal-article","created":{"date-parts":[[2021,1,5]],"date-time":"2021-01-05T09:40:55Z","timestamp":1609839655000},"page":"40-49","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Metabolism and Mechanism of Human Cytochrome P450 Enzyme 1A2"],"prefix":"10.2174","volume":"22","author":[{"given":"Jingchao","family":"Guo","sequence":"first","affiliation":[{"name":"National Reference Laboratory of Veterinary Drug Residues (HZAU) and MAO Key Laboratory for Detection of Veterinary Drug Residues, Huazhong Agricultural University, Wuhan, Hubei 430070, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Zhu","sequence":"additional","affiliation":[{"name":"National Reference Laboratory of Veterinary Drug Residues (HZAU) and MAO Key Laboratory for Detection of Veterinary Drug Residues, Huazhong Agricultural University, Wuhan, Hubei 430070, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Badawy","sequence":"additional","affiliation":[{"name":"National Reference Laboratory of Veterinary Drug Residues (HZAU) and MAO Key Laboratory for Detection of Veterinary Drug Residues, Huazhong Agricultural University, Wuhan, Hubei 430070, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awais","family":"Ihsan","sequence":"additional","affiliation":[{"name":"National Reference Laboratory of Veterinary Drug Residues (HZAU) and MAO Key Laboratory for Detection of Veterinary Drug Residues, Huazhong Agricultural University, Wuhan, Hubei 430070, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenli","family":"Liu","sequence":"additional","affiliation":[{"name":"National Reference Laboratory of Veterinary Drug Residues (HZAU) and MAO Key Laboratory for Detection of Veterinary Drug Residues, Huazhong Agricultural University, Wuhan, Hubei 430070, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changqing","family":"Xie","sequence":"additional","affiliation":[{"name":"National Reference Laboratory of Veterinary Drug Residues (HZAU) and MAO Key Laboratory for Detection of Veterinary Drug Residues, Huazhong Agricultural University, Wuhan, Hubei 430070, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Wang","sequence":"additional","affiliation":[{"name":"National Reference Laboratory of Veterinary Drug Residues (HZAU) and MAO Key Laboratory for Detection of Veterinary Drug Residues, Huazhong Agricultural University, Wuhan, Hubei 430070, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00008571-200401000-00001","volume":"14","author":"Nelson D.R.","year":"2004","unstructured":"Nelson D.R.; Zeldin D.C.; Hoffman S.M.; Maltais L.J.; Wain H.M.; Nebert D.W.; Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 2004,14(1),1-18","journal-title":"Pharmacogenetics"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S0076-6879(96)72007-4","volume":"272","author":"Estabrook R.W.","year":"1996","unstructured":"Estabrook R.W.; Faulkner K.M.; Shet M.S.; Fisher C.W.; Application of electrochemistry for P450-catalyzed reactions. Methods Enzymol 1996,272,44-51","journal-title":"Methods Enzymol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"713","DOI":"10.2174\/138920009789895552","volume":"10","author":"Zhou S.F.","year":"2009","unstructured":"Zhou S.F.; Chan E.; Zhou Z.W.; Xue C.C.; Lai X.; Duan W.; Insights into the structure, function, and regulation of human cytochrome P450 1A2. Curr Drug Metab 2009,10(7),713-729","journal-title":"Curr Drug Metab"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.clpt.2003.12.005","volume":"75","author":"Granfors M.T.","year":"2004","unstructured":"Granfors M.T.; Backman J.T.; Neuvonen M.; Ahonen J.; Neuvonen P.J.; Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction. Clin Pharmacol Ther 2004,75(4),331-341","journal-title":"Clin Pharmacol Ther"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/00008571-199204000-00004","volume":"2","author":"Gu L.","year":"1992","unstructured":"Gu L.; Gonzalez F.J.; Kalow W.; Tang B.K.; Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics 1992,2(2),73-77","journal-title":"Pharmacogenetics"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/00007691-200008000-00008","volume":"22","author":"Carrillo J.A.","year":"2000","unstructured":"Carrillo J.A.; Christensen M.; Ramos S.I.; Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine. 2000,22(4),409-417"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/BF00226333","volume":"49","author":"Ha H.R.","year":"1996","unstructured":"Ha H.R.; Chen J.; Krahenbuhl S.; Follath F.; Biotransformation of caffeine by cDNA-expressed human cytochromes P-450. Eur J Clin Pharmacol 1996,49(4),309-315","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=8","first-page":"543","volume":"76","author":"Kot M.","unstructured":"Kot M.; Daniel W.a.a.A.; The relative contribution of human cytochrome P450 isoforms to the four caffeine oxidation pathways: An in vitro comparative study with cDNA-expressed P450s including CYP2C isoforms. ,76(4),543-551"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"671","DOI":"10.3109\/00498259209053129","volume":"22","author":"Berthou F.","year":"1992","unstructured":"Berthou F.; Guillois B.; Riche C.; Dreano Y.; Jacqz-Aigrain E.; Beaune P.H.; Interspecies variations in caffeine metabolism related to cytochrome P4501A enzymes. Xenobiotica 1992,22(6),671-680","journal-title":"Xenobiotica"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/bmc.736","volume":"21","author":"Begas E.","year":"2007","unstructured":"Begas E.; Kouvaras E.; Tsakalof A.; Papakosta S.; Asprodini E.K.; In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios. Biomed Chromatogr 2007,21(2),190-200","journal-title":"Biomed Chromatogr"},{"key":"ref=11","doi-asserted-by":"publisher","DOI":"10.1007\/s00214-015-1690-y","volume":"134","author":"Chen Z.Q.","year":"2015","unstructured":"Chen Z.Q.; Kang Y.; Zhang C.H.; Metabolic mechanisms of caffeine catalyzed by cytochrome P450 isoenzyme 1A2: a theoretical study. Theor Chem Acc 2015,134(9)","journal-title":"Theor Chem Acc"},{"key":"ref=12","first-page":"237","volume":"15","author":"Campbell M.E.","year":"1987","unstructured":"Campbell M.E.; Grant D.M.; Inaba T.; Kalow W.; Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes. Drug Metab Dispos 1987,15(2),237-249","journal-title":"Drug Metab Dispos"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jmgm.2015.06.017","volume":"61","author":"Tao J.","year":"2015","unstructured":"Tao J.; Kang Y.; Xue Z.; Wang Y.; Zhang Y.; Chen Q.; Chen Z.; Xue Y.; Theoretical study on the N-demethylation mechanism of theobromine catalyzed by P450 isoenzyme 1A2. J Mol Graph Model 2015,61,123-132","journal-title":"J Mol Graph Model"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1177\/00912700122010717","volume":"41","author":"Olesen O.V.","year":"2001","unstructured":"Olesen O.V.; Linnet K.; Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations. J Clin Pharmacol 2001,41(8),823-832","journal-title":"J Clin Pharmacol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/j.bcp.2012.08.015","volume":"84","author":"Kobayashi Y.","year":"2012","unstructured":"Kobayashi Y.; Fukami T.; Higuchi R.; Nakajima M.; Yokoi T.; Metabolic activation by human arylacetamide deacetylase, CYP2E1, and CYP1A2 causes phenacetin-induced methemoglobinemia. Biochem Pharmacol 2012,84(9),1196-1206","journal-title":"Biochem Pharmacol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1046\/j.1365-2125.1997.t01-1-00605.x","volume":"44","author":"Eiermann B.","year":"1997","unstructured":"Eiermann B.; Engel G.; Johansson I.; Zanger U.M.; Bertilsson L.; The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol 1997,44(5),439-446","journal-title":"Br J Clin Pharmacol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1177\/026988110001400403","volume":"14","author":"Aitchison K.J.","year":"2000","unstructured":"Aitchison K.J.; Jann M.W.; Zhao J.H.; Sakai T.; Zaher H.; Wolff K.; Collier D.A.; Kerwin R.W.; Gonzalez F.J.; Clozapine pharmacokinetics and pharmacodynamics studied with Cyp1A2-null mice. J Psychopharmacol 2000,14(4),353-359","journal-title":"J Psychopharmacol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/S0278-5846(01)00320-7","volume":"26","author":"Dailly E.","year":"2002","unstructured":"Dailly E.; Urien S.; Chanut E.; Claudel B.; Guerra N.; Femandez C.; Jolliet P.; Bourin M.; Evidence from a population pharmacokinetics analysis for a major effect of CYP1A2 activity on inter- and intraindividual variations of clozapine clearance. Prog Neuropsychopharmacol Biol Psychiatry 2002,26(4),699-703","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1097\/00007691-199610000-00011","volume":"18","author":"Bartoli A.","year":"1996","unstructured":"Bartoli A.; Xiaodong S.; Gatti G.; Cipolla G.; Marchiselli R.; Perucca E.; The influence of ethnic factors and gender on CYP1A2-mediated drug disposition: a comparative study in Caucasian and Chinese subjects using phenacetin as a marker substrate. Ther Drug Monit 1996,18(5),586-591","journal-title":"Ther Drug Monit"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1124\/jpet.103.055798","volume":"308","author":"Murayama N.","year":"2004","unstructured":"Murayama N.; Soyama A.; Saito Y.; Nakajima Y.; Komamura K.; Ueno K.; Kamakura S.; Kitakaze M.; Kimura H.; Goto Y.; Saitoh O.; Katoh M.; Ohnuma T.; Kawai M.; Sugai K.; Ohtsuki T.; Suzuki C.; Minami N.; Ozawa S.; Sawada J.; Six novel nonsynonymous CYP1A2 gene polymorphisms: catalytic activities of the naturally occurring variant enzymes. J Pharmacol Exp Ther 2004,308(1),300-306","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s12539-014-0184-2","volume":"6","author":"Ma L.N.","year":"2014","unstructured":"Ma L.N.; Du Z.Z.; Lian P.; Wei D.Q.; A theoretical study on the mechanism of a superficial mutation inhibiting the enzymatic activity of CYP1A2. Interdiscip Sci 2014,6(1),25-31","journal-title":"Interdiscip Sci"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1124\/dmd.109.030767","volume":"38","author":"Huang Q.","year":"2010","unstructured":"Huang Q.; Szklarz G.D.; Significant increase in phenacetin oxidation on L382V substitution in human cytochrome P450 1A2. Drug Metab Dispos 2010,38(7),1039-1045","journal-title":"Drug Metab Dispos"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"E1580","DOI":"10.3390\/ijms19061580","volume":"19","author":"Huang Q.","year":"2018","unstructured":"Huang Q.; Szklarz G.D.; Increased Phenacetin Oxidation upon the L382V Substitution in Cytochrome P450 1A2 is Associated with Altered Substrate Binding Orientation. Int J Mol Sci 2018,19(6),E1580","journal-title":"Int J Mol Sci"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s00214-016-1943-4","volume":"135","author":"Xue Z.Y.","year":"2016","unstructured":"Xue Z.Y.; Zhang Y.; Tao J.; Theoretical elucidation of the metabolic mechanisms of phenothiazine neuroleptic chlorpromazine catalyzed by cytochrome P450 isoenzyme 1A2. Theor Chem Acc 2016,135(9),218","journal-title":"Theor Chem Acc"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.dmpk.2015.05.005","volume":"30","author":"Kwon S.S.","year":"2015","unstructured":"Kwon S.S.; Kim J.H.; Jeong H.U.; Ahn K.S.; Oh S.R.; Lee H.S.; Role of cytochrome P450 and UDP-glucuronosyltransferases in metabolic pathway of homoegonol in human liver microsomes. Drug Metab Pharmacokinet 2015,30(4),305-313","journal-title":"Drug Metab Pharmacokinet"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1006\/abbi.1994.1041","volume":"308","author":"Nemoto N.","year":"1994","unstructured":"Nemoto N.; Sakurai J.; Elevated expression of the Cyp1a2 gene in the presence of nicotinamide by adult mouse hepatocytes in primary culture. Arch Biochem Biophys 1994,308(1),292-298","journal-title":"Arch Biochem Biophys"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jpba.2013.03.006","volume":"80","author":"Nobilis M.","year":"2013","unstructured":"Nobilis M.; Miku\u0161ek J.; Szot\u00e1kov\u00e1 B.; Jir\u00e1sko R.; Hol\u010dapek M.; Chamseddin C.; Jira T.; Ku\u010dera R.; Kune\u0161 J.; Pour M.; Analytical power of LLE-HPLC-PDA-MS\/MS in drug metabolism studies: identification of new nabumetone metabolites. J Pharm Biomed Anal 2013,80,164-172","journal-title":"J Pharm Biomed Anal"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1248\/bpb.34.734","volume":"34","author":"Matsumoto K.","year":"2011","unstructured":"Matsumoto K.; Nemoto E.; Hasegawa T.; Akimoto M.; Sugibayashi K.; in vitro characterization of the cytochrome P450 isoforms involved in the metabolism of 6-methoxy-2-napthylacetic acid, an active metabolite of the prodrug nabumetone. Biol Pharm Bull 2011,34(5),734-739","journal-title":"Biol Pharm Bull"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1124\/dmd.108.025700","volume":"37","author":"Turpeinen M.","year":"2009","unstructured":"Turpeinen M.; Hofmann U.; Klein K.; M\u00fcrdter T.; Schwab M.; Zanger U.M.; A predominate role of CYP1A2 for the metabolism of nabumetone to the active metabolite, 6-methoxy-2-naphthylacetic acid, in human liver microsomes. Drug Metab Dispos 2009,37(5),1017-1024","journal-title":"Drug Metab Dispos"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/cpt.1233","volume":"105","author":"Chaugai S.","year":"2019","unstructured":"Chaugai S.; Dickson A.L.; Shuey M.M.; Feng Q.; Barker K.A.; Wei W.Q.; Luther J.M.; Stein C.M.; Chung C.P.; Co-prescription of strong CYP1A2 inhibitors and the risk of tizanidine-associated hypotension: a retrospective cohort study. Clin Pharmacol Ther 2019,105(3),703-709","journal-title":"Clin Pharmacol Ther"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1046\/j.1365-2125.2003.02028.x","volume":"57","author":"Granfors M.T.","year":"2004","unstructured":"Granfors M.T.; Backman J.T.; Laitila J.; Neuvonen P.J.; Tizanidine is mainly metabolized by cytochrome p450 1A2 in vitro. Br J Clin Pharmacol 2004,57(3),349-353","journal-title":"Br J Clin Pharmacol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.3109\/00498258909043177","volume":"19","author":"Koch P.","year":"1989","unstructured":"Koch P.; Hirst DR.; von Wartburg BR.; Biological fate of sirdalud in animals and man. Xenobiotica 1989,19(11),1255-1265","journal-title":"Xenobiotica"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1177\/030006058901700611","volume":"17","author":"Hutchinson D.R.","year":"1989","unstructured":"Hutchinson D.R.; Modified release tizanidine: a review. J Int Med Res 1989,17(6),565-573","journal-title":"J Int Med Res"},{"key":"ref=34","first-page":"S29","volume":"44","author":"Roberts R.C.","year":"1994","unstructured":"Roberts R.C.; Part N.J.; Pokorny R.; Muir C.; Leslie G.C.; Emre M.; Pharmacokinetics and pharmacodynamics of tizanidine. Neurology 1994,44(11)(Suppl. 9),S29-S31","journal-title":"Neurology"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.clpt.2004.08.018","volume":"76","author":"Granfors M.T.","year":"2004","unstructured":"Granfors M.T.; Backman J.T.; Neuvonen M.; Neuvonen P.J.; Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. Clin Pharmacol Ther 2004,76(6),598-606","journal-title":"Clin Pharmacol Ther"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.mrrev.2018.10.002","volume":"778","author":"Deng J.","year":"2018","unstructured":"Deng J.; Zhao L.; Zhang N.Y.; Karrow N.A.; Krumm C.S.; Qi D.S.; Sun L.H.; Aflatoxin B metabolism: regulation by phase I and II metabolizing enzymes and chemoprotective agents. Mutat Res 2018,778,79-89","journal-title":"Mutat Res"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"E158","DOI":"10.3390\/toxins11030158","volume":"11","author":"Wu J.","year":"2019","unstructured":"Wu J.; Zhu S.; Wu Y.; Jiang T.; Wang L.; Jiang J.; Wen J.; Deng Y.; Multiple CH\/\u03c0 interactions maintain the binding of aflatoxin B in the active cavity of human cytochrome P450 1A2. Toxins (Basel) 2019,11(3),E158","journal-title":"Toxins (Basel)"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.bcp.2019.05.031","volume":"166","author":"Zhu S.","year":"2019","unstructured":"Zhu S.; Wu J.; Liu S.; Jiang T.; Deng Y.; Phe-125 and Phe-226 of pig cytochrome P450 1A2 stabilize the binding of aflatoxin B and 7-ethoxyresorufin through the key CH\/\u03c0 interactions. Biochem Pharmacol 2019,166,292-299","journal-title":"Biochem Pharmacol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1007\/s002040100270","volume":"75","author":"Masubuchi Y.","year":"2001","unstructured":"Masubuchi Y.; Nakano T.; Ose A.; Horie T.; Differential selectivity in carbamazepine-induced inactivation of cytochrome P450 enzymes in rat and human liver. Arch Toxicol 2001,75(9),538-543","journal-title":"Arch Toxicol"},{"key":"ref=40","first-page":"338","volume":"26","author":"Masubuchi Y.","year":"1998","unstructured":"Masubuchi Y.; Horie T.; Dihydralazine-induced inactivation of cytochrome P450 enzymes in rat liver microsomes. Drug Metab Dispos 1998,26(4),338-342","journal-title":"Drug Metab Dispos"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s00228-001-0396-3","volume":"57","author":"Wen X.","year":"2002","unstructured":"Wen X.; Wang J.S.; Neuvonen P.J.; Backman J.T.; Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes. Eur J Clin Pharmacol 2002,57(11),799-804","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1124\/dmd.106.011965","volume":"34","author":"Karjalainen M.J.","year":"2006","unstructured":"Karjalainen M.J.; Neuvonen P.J.; Backman J.T.; Rofecoxib is a potent, metabolism-dependent inhibitor of CYP1A2: implications for in vitro prediction of drug interactions. Drug Metab Dispos 2006,34(12),2091-2096","journal-title":"Drug Metab Dispos"},{"key":"ref=43","first-page":"407","volume":"54","author":"W\u00f3jcikowski J.","year":"2002","unstructured":"W\u00f3jcikowski J.; Pichard-Garcia L.; Maurel P.; Daniel W.A.; Perazine as a potent inhibitor of human CYP1A2 but not CYP3A4. Pol J Pharmacol 2002,54(4),407-410","journal-title":"Pol J Pharmacol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1002\/jcph.1377","volume":"59","author":"Sorich M.J.","year":"2019","unstructured":"Sorich M.J.; Mutlib F.; van Dyk M.; Hopkins A.M.; Polasek T.M.; Marshall J.C.; Rodrigues A.D.; Rowland A.; Use of physiologically based pharmacokinetic modeling to identify physiological and molecular characteristics driving variability in axitinib exposure: a fresh approach to precision dosing in oncology. J Clin Pharmacol 2019,59(6),872-879","journal-title":"J Clin Pharmacol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.bcp.2014.01.016","volume":"88","author":"Gu R.","year":"2014","unstructured":"Gu R.; Hibbs D.E.; Ong J.A.; Edwards R.J.; Murray M.; The multikinase inhibitor axitinib is a potent inhibitor of human CYP1A2. Biochem Pharmacol 2014,88(2),245-252","journal-title":"Biochem Pharmacol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1021\/tx00035a009","volume":"6","author":"Kunze K.L.","year":"1993","unstructured":"Kunze K.L.; Trager W.F.; Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem Res Toxicol 1993,6(5),649-656","journal-title":"Chem Res Toxicol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1046\/j.1365-2125.1998.00679.x","volume":"45","author":"Eagling V.A.","year":"1998","unstructured":"Eagling V.A.; Tjia J.F.; Back D.J.; Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Br J Clin Pharmacol 1998,45(2),107-114","journal-title":"Br J Clin Pharmacol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1365-2125.1987.tb03003.x","volume":"23","author":"Tarrus E.","year":"1987","unstructured":"Tarrus E.; Cami J.; Roberts D.J.; Spickett R.G.; Celdran E.; Segura J.; Accumulation of caffeine in healthy volunteers treated with furafylline. Br J Clin Pharmacol 1987,23(1),9-18","journal-title":"Br J Clin Pharmacol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"6555","DOI":"10.21873\/anticanres.13871","volume":"39","author":"Lee M.Y.","year":"2019","unstructured":"Lee M.Y.; Shi C.S.; Hsu Y.C.; Huang K.J.; Chen S.H.; Zhao P.W.; Chung H.C.; Huang Y.C.; Lee Y.R.; Honokiol is a potential therapeutic agent and has a synergistic effect with 5-FU in human urothelial cell carcinoma cells. Anticancer Res 2019,39(12),6555-6565","journal-title":"Anticancer Res"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/rcm.8314","volume":"33","author":"Huang Y.","year":"2019","unstructured":"Huang Y.; Liu C.; Liu S.; Liu Z.; Li S.; Wang Y.; In vitro metabolism of magnolol and honokiol in rat liver microsomes and their interactions with seven cytochrome P substrates. Rapid Commun Mass Spectrom 2019,33(2),229-238","journal-title":"Rapid Commun Mass Spectrom"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s13318-019-00565-9","volume":"44","author":"Li J.","year":"2019","unstructured":"Li J.; Li M.R.; Sun B.; Liu C.M.; Ren J.; Zhi W.Q.; Zhang P.Y.; Qiao H.L.; Gao N.; Inhibition of rat CYP1A2 and CYP2C11 by honokiol, a component of traditional Chinese medicine. Eur J Drug Metab Pharmacokinet 2019,44(6),787-796","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00228-007-0456-4","volume":"64","author":"Karjalainen M.J.","year":"2008","unstructured":"Karjalainen M.J.; Neuvonen P.J.; Backman J.T.; Celecoxib is a CYP1A2 inhibitor in vitro but not in vivo. Eur J Clin Pharmacol 2008,64(5),511-519","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1124\/dmd.31.11.1398","volume":"31","author":"Slaughter D.","year":"2003","unstructured":"Slaughter D.; Takenaga N.; Lu P.; Assang C.; Walsh D.J.; Arison B.H.; Cui D.; Halpin R.A.; Geer L.A.; Vyas K.P.; Baillie T.A.; Metabolism of rofecoxib in vitro using human liver subcellular fractions. Drug Metab Dispos 2003,31(11),1398-1408","journal-title":"Drug Metab Dispos"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1177\/0091270003257454","volume":"43","author":"Bachmann K.","year":"2003","unstructured":"Bachmann K.; White D.; Jauregui L.; Schwartz J.I.; Agrawal N.G.; Mazenko R.; Larson P.J.; Porras A.G.; An evaluation of the dose-dependent inhibition of CYP1A2 by rofecoxib using theophylline as a CYP1A2 probe. J Clin Pharmacol 2003,43(10),1082-1090","journal-title":"J Clin Pharmacol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/j.1365-2125.2006.02653.x","volume":"62","author":"Backman J.T.","year":"2006","unstructured":"Backman J.T.; Karjalainen M.J.; Neuvonen M.; Laitila J.; Neuvonen P.J.; Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects. Br J Clin Pharmacol 2006,62(3),345-357","journal-title":"Br J Clin Pharmacol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S1734-1140(09)70141-0","volume":"61","author":"W\u00f3jcikowski J.","year":"2009","unstructured":"W\u00f3jcikowski J.; Daniel W.A.; Perazine at therapeutic drug concentrations inhibits human cytochrome P450 isoenzyme 1A2 (CYP1A2) and caffeine metabolism-an in vitro study. Pharmacol Rep 2009,61(5),851-858","journal-title":"Pharmacol Rep"},{"key":"ref=57","first-page":"88","volume":"294","author":"Obach R.S.","year":"2000","unstructured":"Obach R.S.; Inhibition of human cytochrome P450 enzymes by constituents of St. John\u2019s Wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther 2000,294(1),88-95","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1211\/0022357044021","volume":"56","author":"von Moltke L.L.","year":"2004","unstructured":"von Moltke L.L.; Weemhoff J.L.; Bedir E.; Khan I.A.; Harmatz J.S.; Goldman P.; Greenblatt D.J.; Inhibition of human cytochromes P450 by components of Ginkgo biloba. J Pharm Pharmacol 2004,56(8),1039-1044","journal-title":"J Pharm Pharmacol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00228-003-0596-0","volume":"59","author":"Peng W.X.","year":"2003","unstructured":"Peng W.X.; Li H.D.; Zhou H.H.; Effect of daidzein on CYP1A2 activity and pharmacokinetics of theophylline in healthy volunteers. Eur J Clin Pharmacol 2003,59(3),237-241","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3109\/00498254.2015.1053006","volume":"46","author":"Manda Vk A.B.","year":"2016","unstructured":"Manda Vk A.B.; Inhibition of CYP3A4 and CYP1A2 by aegle marmelos and its constituents. Xenobiotica 2016,46(2),117-125","journal-title":"Xenobiotica"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.fct.2012.09.013","volume":"51","author":"Kim H.","year":"2013","unstructured":"Kim H.; Choi HK.; Jeong TC.; Selective inhibitory effects of mollugin on CYP1A2 in human liver microsomes. Food Chem Toxicol 2013,51,33-37","journal-title":"Food Chem Toxicol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"e89752","DOI":"10.1371\/journal.pone.0089752","volume":"9","author":"Gao N.","year":"2014","unstructured":"Gao N.; Qi B.; Liu F.J.; Fang Y.; Zhou J.; Jia L.J.; Qiao H.L.; Inhibition of baicalin on metabolism of phenacetin, a probe of CYP1A2, in human liver microsomes and in rats. PLoS One 2014,9(2),e89752","journal-title":"PLoS One"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.bbagen.2006.07.005","volume":"1770","author":"Cojocaru V.","year":"2007","unstructured":"Cojocaru V.; Winn P.J.; Wade R.C.; The ins and outs of cytochrome P450s. Biochim Biophys Acta 2007,1770(3),390-401","journal-title":"Biochim Biophys Acta"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"269","DOI":"10.2133\/dmpk.24.269","volume":"24","author":"Miyajima A.","year":"2009","unstructured":"Miyajima A.; Furihata T.; Chiba K.; Functional analysis of GC Box and its CpG methylation in the regulation of CYP1A2 gene expression. Drug Metab Pharmacokinet 2009,24(3),269-276","journal-title":"Drug Metab Pharmacokinet"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.freeradbiomed.2003.11.013","volume":"36","author":"Shertzer H.G.","year":"2004","unstructured":"Shertzer H.G.; Clay C.D.; Genter M.B.; Schneider S.N.; Nebert D.W.; Dalton T.P.; Cyp1a2 protects against reactive oxygen production in mouse liver microsomes. Free Radic Biol Med 2004,36(5),605-617","journal-title":"Free Radic Biol Med"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1124\/dmd.107.015826","volume":"35","author":"Ma Q.","year":"2007","unstructured":"Ma Q.; Lu A.Y.; CYP1A induction and human risk assessment: an evolving tale of in vitro and in vivo studies. Drug Metab Dispos 2007,35(7),1009-1016","journal-title":"Drug Metab Dispos"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"15510","DOI":"10.1021\/bi048736m","volume":"43","author":"Ogiso H.","year":"2004","unstructured":"Ogiso H.; Kagi N.; Matsumoto E.; Nishimoto M.; Arai R.; Shirouzu M.; Mimura J.; Fujii-Kuriyama Y.; Yokoyama S.; Phosphorylation analysis of 90 kDa heat shock protein within the cytosolic arylhydrocarbon receptor complex. Biochemistry 2004,43(49),15510-15519","journal-title":"Biochemistry"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1124\/mol.106.029215","volume":"70","author":"Hollingshead B.D.","year":"2006","unstructured":"Hollingshead B.D.; Patel R.D.; Perdew G.H.; Endogenous hepatic expression of the hepatitis B virus X-associated protein 2 is adequate for maximal association with aryl hydrocarbon receptor-90-kDa heat shock protein complexes. Mol Pharmacol 2006,70(6),2096-2107","journal-title":"Mol Pharmacol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1093\/oxfordjournals.jbchem.a123562","volume":"110","author":"Kubota M.","year":"1991","unstructured":"Kubota M.; Sogawa K.; Kaizu Y.; Sawaya T.; Watanabe J.; Kawajiri K.; Gotoh O.; Fujii-Kuriyama Y.; Xenobiotic responsive element in the 5\u2032-upstream region of the human P-450c gene. J Biochem 1991,110(2),232-236","journal-title":"J Biochem"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"15001","DOI":"10.1074\/jbc.M300645200","volume":"278","author":"Yueh M.F.","year":"2003","unstructured":"Yueh M.F.; Huang Y.H.; Hiller A.; Chen S.; Nguyen N.; Tukey R.H.; Involvement of the xenobiotic response element (XRE) in Ah receptor-mediated induction of human UDP-glucuronosyltransferase 1A1. J Biol Chem 2003,278(17),15001-15006","journal-title":"J Biol Chem"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/tpj.2009.4","volume":"9","author":"Ghotbi R.","year":"2009","unstructured":"Ghotbi R.; Gomez A.; Milani L.; Tybring G.; Syv\u00e4nen A.C.; Bertilsson L.; Ingelman-Sundberg M.; Aklillu E.; Allele-specific expression and gene methylation in the control of CYP1A2 mRNA level in human livers. Pharmacogenomics J 2009,9(3),208-217","journal-title":"Pharmacogenomics J"},{"key":"ref=72","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3109\/00498254.2014.973930","volume":"45","author":"Awortwe C.","year":"2015","unstructured":"Awortwe C.; Manda VK.; Avonto C.; Echinacea purpurea up-regulates CYP1A2, CYP3A4 and MDR1 gene expression by activation of pregnane X receptor pathway. Xenobiotica 2015,45(3),218-229","journal-title":"Xenobiotica"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.bcp.2009.08.008","volume":"79","author":"Yoshinari K.","year":"2010","unstructured":"Yoshinari K.; Yoda N.; Toriyabe T.; Yamazoe Y.; Constitutive androstane receptor transcriptionally activates human CYP1A1 and CYP1A2 genes through a common regulatory element in the 5\u2032-flanking region. Biochem Pharmacol 2010,79(2),261-269","journal-title":"Biochem Pharmacol"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"24","DOI":"10.2133\/dmpk.20.24","volume":"20","author":"Soyama A.","year":"2005","unstructured":"Soyama A.; Saito Y.; Hanioka N.; Maekawa K.; Komamura K.; Kamakura S.; Kitakaze M.; Tomoike H.; Ueno K.; Goto Y.; Kimura H.; Katoh M.; Sugai K.; Saitoh O.; Kawai M.; Ohnuma T.; Ohtsuki T.; Suzuki C.; Minami N.; Kamatani N.; Ozawa S.; Sawada J.; Single nucleotide polymorphisms and haplotypes of CYP1A2 in a Japanese population. Drug Metab Pharmacokinet 2005,20(1),24-33","journal-title":"Drug Metab Pharmacokinet"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S0009-9236(03)00013-4","volume":"73","author":"Obase Y.","year":"2003","unstructured":"Obase Y.; Shimoda T.; Kawano T.; Saeki S.; Tomari S.Y.; Mitsuta-Izaki K.; Matsuse H.; Kinoshita M.; Kohno S.; Polymorphisms in the CYP1A2 gene and theophylline metabolism in patients with asthma. Clin Pharmacol Ther 2003,73(5),468-474","journal-title":"Clin Pharmacol Ther"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"231","DOI":"10.5415\/apallergy.2013.3.4.231","volume":"3","author":"Yim E.Y.","year":"2013","unstructured":"Yim E.Y.; Kang H.R.; Jung J.W.; Sohn S.W.; Cho S.H.; CYP1A2 polymorphism and theophylline clearance in Korean non-smoking asthmatics. Asia Pac Allergy 2013,3(4),231-240","journal-title":"Asia Pac Allergy"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s00228-007-0288-2","volume":"63","author":"Ghotbi R.","year":"2007","unstructured":"Ghotbi R.; Christensen M.; Roh H.K.; Ingelman-Sundberg M.; Aklillu E.; Bertilsson L.; Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol 2007,63(6),537-546","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0016-5085(99)70554-8","volume":"117","author":"Fontana R.J.","year":"1999","unstructured":"Fontana R.J.; Lown K.S.; Paine M.F.; Fortlage L.; Santella R.M.; Felton J.S.; Knize M.G.; Greenberg A.; Watkins P.B.; Effects of a chargrilled meat diet on expression of CYP3A, CYP1A, and P-glycoprotein levels in healthy volunteers. Gastroenterology 1999,117(1),89-98","journal-title":"Gastroenterology"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1093\/carcin\/21.6.1157","volume":"21","author":"Lampe J.W.","year":"2000","unstructured":"Lampe J.W.; King I.B.; Li S.; Grate M.T.; Barale K.V.; Chen C.; Feng Z.; Potter J.D.; Brassica vegetables increase and apiaceous vegetables decrease cytochrome P450 1A2 activity in humans: changes in caffeine metabolite ratios in response to controlled vegetable diets. Carcinogenesis 2000,21(6),1157-1162","journal-title":"Carcinogenesis"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1097\/00042737-199610001-00005","volume":"8","author":"Meyer U.A.","year":"1996","unstructured":"Meyer U.A.; Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs. Eur J Gastroenterol Hepatol 1996,8(Suppl. 1),S21-S25","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/clpt.1982.157","volume":"32","author":"Kotake A.N.","year":"1982","unstructured":"Kotake A.N.; Schoeller D.A.; Lambert G.H.; Baker A.L.; Schaffer D.D.; Josephs H.; The caffeine CO2 breath test: dose response and route of N-demethylation in smokers and nonsmokers. Clin Pharmacol Ther 1982,32(2),261-269","journal-title":"Clin Pharmacol Ther"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/j.1365-2125.1988.tb03393.x","volume":"26","author":"Sesardic D.","year":"1988","unstructured":"Sesardic D.; Boobis A.R.; Edwards R.J.; Davies D.S.; A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. Br J Clin Pharmacol 1988,26(4),363-372","journal-title":"Br J Clin Pharmacol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1046\/j.1365-2125.1998.00684.x","volume":"45","author":"Parker A.C.","year":"1998","unstructured":"Parker A.C.; Pritchard P.; Preston T.; Choonara I.; Induction of CYP1A2 activity by carbamazepine in children using the caffeine breath test. Br J Clin Pharmacol 1998,45(2),176-178","journal-title":"Br J Clin Pharmacol"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.bcp.2008.04.005","volume":"76","author":"Yoshinari K.","year":"2008","unstructured":"Yoshinari K.; Ueda R.; Kusano K.; Yoshimura T.; Nagata K.; Yamazoe Y.; Omeprazole transactivates human CYP1A1 and CYP1A2 expression through the common regulatory region containing multiple xenobiotic-responsive elements. Biochem Pharmacol 2008,76(1),139-145","journal-title":"Biochem Pharmacol"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3109\/00498254.2015.1060371","volume":"46","author":"Tang J.","year":"2016","unstructured":"Tang J.; Ji H.; Shi J.; Wu L.; Ephedra water decoction and cough tablets containing ephedra and liquorice induce CYP1A2 but not CYP2E1 hepatic enzymes in rats. Xenobiotica 2016,46(2),141-146","journal-title":"Xenobiotica"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.3389\/fphar.2019.01575","volume":"10","author":"Li X.Y.","year":"2020","unstructured":"Li X.Y.; Qu N.; Wang X.J.; Yang J.X.; Xin Y.Y.; Zhu J.B.; Bai X.; Duan Y.B.; Regulation of X-ray irradiation on the activity and expression levels of CYP1A2 and CYP2E1 in rats. Front Pharmacol 2020,10,1575","journal-title":"Front Pharmacol"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1159\/000455154","volume":"99","author":"Liu S.","year":"2017","unstructured":"Liu S.; Cheng Y.; Rao M.; Tang M.; Dong Z.; Muscone induces CYP1A2 and CYP3A4 enzyme expression in L02 human liver cells and CYP1A2 and CYP3A11 Enzyme Expression in Kunming mice. Pharmacology 2017,99(5-6),205-215","journal-title":"Pharmacology"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"195","DOI":"10.2174\/1872312810666160719143703","volume":"10","author":"Liu H.","year":"2016","unstructured":"Liu H.; Narayanan R.; Hoffmann M.; Surapaneni S.; The uremic toxin indoxyl-3-sulfate induces CYP1A2 in primary human hepatocytes. Drug Metab Lett 2016,10(3),195-199","journal-title":"Drug Metab Lett"},{"key":"ref=89","doi-asserted-by":"publisher","DOI":"10.4238\/gmr.15027487","volume":"15","author":"Denden S.","year":"2016","unstructured":"Denden S.; Bouden B.; Haj Khelil A.; Ben Chibani J.; Hamdaoui M.H.; Gender and ethnicity modify the association between the CYP1A2 rs762551 polymorphism and habitual coffee intake: evidence from a meta-analysis. Genet Mol Res , 10.4238\/gmr.15027487.2016,15(2)","journal-title":"Genet Mol Res"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1177\/0091270005280851","volume":"45","author":"Shelepova T.","year":"2005","unstructured":"Shelepova T.; Nafziger A.N.; Victory J.; Kashuba A.D.; Rowland E.; Zhang Y.; Sellers E.; Kearns G.; Leeder J.S.; Gaedigk A.; Bertino J.S.; Effect of a triphasic oral contraceptive on drug-metabolizing enzyme activity as measured by the validated Cooperstown 5+1 cocktail. J Clin Pharmacol 2005,45(12),1413-1421","journal-title":"J Clin Pharmacol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.ajog.2004.08.030","volume":"192","author":"Tracy T.S.","year":"2005","unstructured":"Tracy T.S.; Venkataramanan R.; Glover D.D.; Caritis S.N.; Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A activity) during pregnancy. Am J Obstet Gynecol National Institute for Child Health and Human Development Network of Maternal-fetal-medicine Units2005,192(2),633-639","journal-title":"Am J Obstet Gynecol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"109074","DOI":"10.1016\/j.envres.2019.109074","volume":"182","author":"Tsiokou V.","year":"2020","unstructured":"Tsiokou V.; Kilindris T.; Begas E.; Kouvaras E.; Kouretas D.; Asprodini E.K.; Altered activity of xenobiotic detoxifying enzymes at menopause - A cross-sectional study. Environ Res 2020,182,109074","journal-title":"Environ Res"}],"container-title":["Current Drug Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/189851","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/189851\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/189851","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T16:46:44Z","timestamp":1632502004000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/189851\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,22]]},"references-count":92,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,3,22]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389200221999210101233135","relation":{},"ISSN":["1389-2002"],"issn-type":[{"value":"1389-2002","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3,22]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-03-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-09","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}